ICAM2 and Crohn disease: A limited number of studies have reported altered expression of ICAM-2, although these include upregulation in clinical scenarios of a more chronic and complex nature, such as lymphoid malignancies (Renkonen et al., 1992) or Crohn's disease (Bernstein et al., 1998), or downregulation through inhibition of transcription following prolonged exposure to cytokines in HUVECs (McLaughlin et al., 1998).